| Name | Title | Contact Details |
|---|
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
Henry Meds is a company that provides affordable treatment for chronic medical conditions through a program that includes both doctors and medication with no hidden fees.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
Stride Autism Centers is a provider of Applied Behavior Analysis (ABA) therapy for preschool children with autism in Illinois, Iowa, and Nebraska.
New Directions Northwest Inc is a Baker City, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.